Encorafenib is primarily used in the treatment of certain types of cancer, particularly melanoma. It is often prescribed in combination with other medications, such as binimetinib, to enhance its effectiveness. This combination therapy targets specific genetic mutations, such as the BRAF V600E or V600K mutations, which are commonly found in melanoma cells. By inhibiting the activity of the mutated BRAF protein, encorafenib helps to slow down or stop the growth of cancer cells. It is also being explored for use in other cancers where BRAF mutations are present, such as colorectal cancer. The drug is typically administered orally, and its use is closely monitored by healthcare professionals to manage potential side effects and ensure optimal therapeutic outcomes.